普洛药业
(000739)
| 流通市值：190.41亿 | | | 总市值：190.48亿 |
| 流通股本：11.69亿 | | | 总股本：11.69亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 9,290,220,207.76 | 6,428,714,752.29 | 3,198,046,619.86 | 11,474,162,365.59 |
| 营业收入 | 9,290,220,207.76 | 6,428,714,752.29 | 3,198,046,619.86 | 11,474,162,365.59 |
| 二、营业总成本 | 8,295,069,270.45 | 5,651,769,473.26 | 2,862,663,780.78 | 10,231,011,582.85 |
| 营业成本 | 7,039,196,715.18 | 4,840,895,523.11 | 2,429,103,622.29 | 8,529,454,580.9 |
| 税金及附加 | 38,464,108.76 | 27,691,554.27 | 8,361,997.65 | 56,089,623.61 |
| 销售费用 | 399,845,866 | 280,576,659.93 | 152,627,121.84 | 658,422,825.05 |
| 管理费用 | 364,405,634.04 | 234,373,187.88 | 123,254,329.94 | 466,546,668.39 |
| 研发费用 | 467,201,967.23 | 314,769,509.42 | 152,938,500.76 | 624,870,084.99 |
| 财务费用 | -14,045,020.76 | -46,536,961.35 | -3,621,791.7 | -104,372,200.09 |
| 其中:利息费用 | 22,658,655.71 | 15,432,755.6 | 8,422,207.91 | 34,230,184.64 |
| 其中:利息收入 | 61,734,298.32 | 38,720,756.24 | 10,977,859.8 | 113,471,341.33 |
| 加:公允价值变动收益 | 8,469,505.02 | -2,535,659.78 | -2,832,381.83 | -19,228.93 |
| 加:投资收益 | -8,133,805.36 | -723,423.58 | -2,018,356.21 | -21,684,708.02 |
| 资产处置收益 | 940,320.95 | 567,328.49 | 278,035.93 | 1,328,848.13 |
| 资产减值损失(新) | -64,057,956.27 | -69,037,026.68 | -30,041,951.83 | -91,833,169.24 |
| 信用减值损失(新) | 4,482,243.72 | -23,456,851.24 | -23,590,931.18 | -14,654,175.46 |
| 其他收益 | 86,271,219.6 | 58,683,210.82 | 23,121,109.72 | 103,853,603.88 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,023,122,464.97 | 740,442,857.06 | 300,298,363.68 | 1,220,141,953.1 |
| 加:营业外收入 | 1,534,043.08 | 910,434.62 | 480,645.43 | 1,423,963.54 |
| 减:营业外支出 | 4,812,177.38 | 2,849,204.9 | 1,289,063 | 16,921,855.91 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,019,844,330.67 | 738,504,086.78 | 299,489,946.11 | 1,204,644,060.73 |
| 减:所得税费用 | 150,456,206.83 | 113,858,949.43 | 55,775,945.03 | 149,337,162.5 |
| 六、净利润 | 869,388,123.84 | 624,645,137.35 | 243,714,001.08 | 1,055,306,898.23 |
| 持续经营净利润 | 869,388,123.84 | 624,645,137.35 | 243,714,001.08 | 1,055,306,898.23 |
| 归属于母公司股东的净利润 | 869,652,417.71 | 624,842,853.55 | 243,716,289.99 | 1,055,340,740.79 |
| 少数股东损益 | -264,293.87 | -197,716.2 | -2,288.91 | -33,842.56 |
| (一)基本每股收益 | 0.75 | 0.54 | 0.21 | 0.9 |
| (二)稀释每股收益 | 0.75 | 0.54 | 0.21 | 0.9 |
| 八、其他综合收益 | 3,571,372.34 | 874,296.24 | 743,150.25 | 2,798,837.27 |
| 归属于母公司股东的其他综合收益 | 3,571,372.34 | 874,296.24 | 743,150.25 | 2,798,837.27 |
| 九、综合收益总额 | 872,959,496.18 | 625,519,433.59 | 244,457,151.33 | 1,058,105,735.5 |
| 归属于母公司股东的综合收益总额 | 873,223,790.05 | 625,717,149.79 | 244,459,440.24 | 1,058,139,578.06 |
| 归属于少数股东的综合收益总额 | -264,293.87 | -197,716.2 | -2,288.91 | -33,842.56 |
| 公告日期 | 2024-10-18 | 2024-08-16 | 2024-04-18 | 2024-03-08 |
| 审计意见(境内) | | | | 标准无保留意见 |